JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics.
Costeas, Paul A
MetadataShow full item record
McKerrell, T., Park, N., Chi, J., Collord, G., Moreno, T., Ponstingl, H., Dias, J., et al. (2017). JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics.. Blood Advances, 1 (14), 968-971. https://doi.org/10.1182/bloodadvances.2017007047
TO THE EDITOR: The JAK2 V617F mutation is the most common somatic mutation in the classical myeloproliferative neoplasms (MPNs), present in >95% of cases of polycythemia vera (PV) and ∼50% of essential thrombocythemia (ET) and myelofibrosis (MF).1⇓⇓-4 It is usually the sole identifiable driver mutation in MPNs5 and was recently also identified as a driver of age-related clonal hemopoiesis in healthy individuals.6⇓⇓-9 In order to investigate the preclinical clonal evolution of MPNs, we identified 12 individuals with a JAK2 V617F mutant MPN, who 4.6 to 15.2 years previously (median 10.2 years) had also donated blood to register with the Cyprus Bone Marrow Donor Registry at the Karaiskakio Foundation
This work was supported by the Wellcome Trust Sanger Institute (WT098051). T. McKerrell is funded by a Wellcome Trust Clinician Scientist Fellowship (100678/Z/12/Z). G.S.V. is funded by a Wellcome Trust Senior Fellowship in Clinical Science (WT095663MA), and work in his laboratory is also funded by Cancer Research UK, Bloodwise, the Kay Kendall Leukaemia Fund, and Celgene. I.V. is supported by the Spanish Ministerio de Economía y Competitividad, Programa Ramón y Cajal.
Wellcome Trust (100678/Z/12/Z)
Academy of Medical Sciences (Unknown)
External DOI: https://doi.org/10.1182/bloodadvances.2017007047
This record's URL: https://www.repository.cam.ac.uk/handle/1810/290973